Immune Design Corp. (NASDAQ:IMDZ) released its earnings results on Wednesday. The biotechnology company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.11, Bloomberg Earnings reports. Immune Design Corp. had a negative return on equity of 64.22% and a negative net margin of 619.62%. The company had revenue of $0.52 million during the quarter, compared to analyst estimates of $0.62 million.

A number of equities research analysts have recently weighed in on the company. ValuEngine lowered Immune Design Corp. from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 21st. Wells Fargo & Company lowered Immune Design Corp. from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $29.00 to $10.00 in a research note on Tuesday, October 17th. Royal Bank Of Canada assumed coverage on Immune Design Corp. in a research note on Thursday, September 14th. They issued an “outperform” rating and a $20.00 target price for the company. BidaskClub lowered Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 5th. Finally, Zacks Investment Research raised Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research note on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Immune Design Corp. presently has a consensus rating of “Buy” and an average target price of $14.75.

In other Immune Design Corp. news, Director Franklin M. Berger purchased 25,000 shares of the stock in a transaction that occurred on Monday, October 30th. The stock was purchased at an average price of $4.58 per share, with a total value of $114,500.00. Following the acquisition, the director now owns 75,000 shares in the company, valued at $343,500. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Leo Guthart purchased 10,000 shares of the stock in a transaction that occurred on Monday, September 18th. The stock was acquired at an average cost of $9.70 per share, with a total value of $97,000.00. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 5,250,000 shares of company stock valued at $21,649,900. 20.70% of the stock is owned by insiders.

An institutional investor recently raised its position in Immune Design Corp. stock. California State Teachers Retirement System lifted its holdings in Immune Design Corp. (NASDAQ:IMDZ) by 8.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 30,174 shares of the biotechnology company’s stock after acquiring an additional 2,300 shares during the period. California State Teachers Retirement System owned 0.12% of Immune Design Corp. worth $294,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 51.44% of the company’s stock.

WARNING: This news story was first reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/immune-design-corp-imdz-releases-earnings-results-beats-expectations-by-0-11-eps/1675514.html.

Immune Design Corp. Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Earnings History for Immune Design Corp. (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.